PJP
Invesco Pharmaceuticals ETF
NYSEArcaUSDETF / FUND
DELAYED
Neutral
+8/100
Last price
120.71
▼ 0.39 (0.32%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
121.10
Day high
121.66
Day low
119.63
Volume
71.14K
Market cap
—
P/E (TTM)
21.60
52W range
92.10 – 131.68
Trailing performance
Returnvs SPY
1W
-4.30%
-6.2%
1M
-6.54%
-7.7%
3M
-0.19%
-4.7%
6M
+17.64%
-0.5%
YTD
+15.47%
+1.2%
1Y
+26.20%
+9.8%
3Y
+66.80%
-15.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Top holdings
| Symbol | Name | Weight | |
|---|---|---|---|
| GILD | Gilead Sciences Inc | 5.64% | |
| PFE | Pfizer Inc | 5.62% | |
| ABBV | AbbVie Inc | 5.54% | |
| JNJ | Johnson & Johnson | 5.45% | |
| AMGN | Amgen Inc | 5.35% | |
| LLY | Eli Lilly and Co | 5.27% | |
| MRK | Merck & Co Inc | 5.22% | |
| ABT | Abbott Laboratories | 4.78% | |
| AMRX | Amneal Pharmaceuticals Inc Ordinary Shares - Class A | 3.60% | |
| LGND | Ligand Pharmaceuticals Inc | 3.55% |
Sector exposure
Healthcare
100.00%
Fund profile
Fund familyInvesco
CategoryHealth
Legal typeExchange Traded Fund
Expense ratio0.58%
Turnover36.0%
Total net assets$35.77M
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on PJP open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E21.60
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
124.00
+2.7% from spot
ATM implied vol
3.1%
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
124.00
0 contracts
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
123.92
-2.59% from price
SMA 20
124.64
-3.15% from price
SMA 50
125.76
-4.02% from price
SMA 100
119.90
+0.67% from price
SMA 200
112.75
+7.06% from price
EMA 12
123.47
-2.24% from price
EMA 26
124.66
-3.17% from price
EMA 50
124.01
-2.66% from price
RSI (14)
35.0
Neutral
MACD (12,26,9)
-1.19
Hist -0.69
ATR (14)
1.74
1.45% of price
Realised vol 30D
15.0%
Annualised
Bollinger upper
128.86
20, 2σ
Bollinger lower
120.41
20, 2σ
50 / 200 cross
Golden
125.76 vs 112.75
Trend bias
Above 200
+7.06%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.44
Less volatile than market
Correlation to SPY
0.34
Loosely linked
Realised vol 30D
15.0%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-9.7%
Peak to trough
Max drawdown 5Y
-18.7%
Peak to trough
ATR 14
1.74
1.45% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
Zacks · 9d ago
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
Zacks · 34d ago
Healthcare ETFs Are Looking Up: Here's Why
Zacks · 49d ago
Will Generic Drug Tariffs Impact Pharma ETFs?
Zacks · 69d ago
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
Zacks · 71d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.